HPB ( IF 2.7 ) Pub Date : 2021-07-26 , DOI: 10.1016/j.hpb.2021.07.002 Hong Zhao 1 , Aiping Zhou 2 , Jianguo Zhou 3 , Xinyu Bi 1 , Shida Yan 3 , Jing Jin 4 , Wenqiang Wei 5 , Muxing Li 6 , Caifeng Gong 2 , Qichen Chen 3 , Zhiwen Luo 3 , Ning Li 4 , Rui Mao 3 , Xiao Chen 3 , Bo Chen 4 , Rongshou Zheng 5 , Jianjun Zhao 3 , Yue Han 7 , Zhiyu Li 3 , Xu Che 8 , Yuan Tang 4 , Yongkun Sun 2 , Zhen Huang 3 , Yefan Zhang 3 , Xiaoying Wang 9 , Yubao Zhang 10 , Zhenhui Lu 11 , Xiaowei Dang 12 , Tianqiang Song 13 , Chang Liu 14 , Ping Yue 15 , Dong Yan 16 , Aimin Yue 17 , Rui Zhang 18 , Suxia Luo 19 , Jing Tan 20 , Xuewen Zhang 21 , Xueli Bai 22 , Xuejun Zhang 23 , Mingyan He 24 , Yujun Xie 25 , Wenling Wang 26 , Po Yang 27 , Yijun Yang 28 , Yamin Zhang 29 , Qingdong Li 30 , Tao Peng 31 , Zusen Wang 32 , Yajin Chen 33 , Changzhen Shang 33 , Yingjian Liang 34 , Bixiang Zhang 35 , Feng Zhang 36 , Liming Wang 37 , Duo Li 38 , Bin Liu 39 , Xiaofeng Zhu 40 , Qinggang Hu 41 , Minshan Chen 42 , Dianrong Xiu 6 , Feng Xia 43 , Yanqiao Zhang 44 , Yong Zeng 45 , Yilei Mao 46 , Xun Li 15 , Yi Ba 47 , Tingbo Liang 22 , Feng Shen 48 , Lianxin Liu 49 , Xiujun Cai 50 , Jian Zhou 9 , Jianqiang Cai 1
Background
This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic.
Methods
A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic.
Results
716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the “face-to-face” visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC.
Discussion
During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.
京公网安备 11010802027423号